Literature DB >> 10815618

Prostaglandin E2 affects differently the release of inflammatory mediators from resident macrophages by LPS and muramyl tripeptides.

P Dieter1, U Hempel, S Kamionka, A Kolada, B Malessa, E Fitzke, T A Tran-Thi.   

Abstract

LPS and MTP-PE (liposome-encapsulated N-acetyl-muramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-:[1',2'dipalmitoyl -sni-glycero-3-(hydroxy-phosphoryl-oxyl)] etylamide) induce in liver macrophages a synthesis and release of TNF-alpha, nitric oxide and prostanoids. Both agents induce an expression of mRNA's encoding TNF-alpha, inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2, and of corresponding proteins. LPS and MTP-PE induce a rapid activation of the extracellular regulated kinase (ERK) isoenzymes-1 and -2. Inhibition of map kinase isoenzymes leads to a decreased release of TNF-alpha, nitric oxide and prostaglandin (PG) E2 after both agents. The transcription factors NF-kappaB and AP-1 are strongly activated by LPS within 30 minutes. MTP-PE induces a weak activation of both transcription factors only after 5 hours. Inhibition of NF-kappaB inhibits the LPS- but not the MTP-PE-induced release of TNF-alpha, nitric oxide and PGE2. PGE2 release after LPS is higher than after MTP-PE. Exogenously added PGE2 inhibits the activation of map kinase and TNF-alpha release by LPS, but not by MTP-PE. Release of nitric oxide after LPS and MTP-PE is enhanced after prior addition of PGE2. PGD2 is without any effect. MTP-PE, but not LPS, induces a cytotoxicity of Kupffer cells against P815 tumor target cells. The MTP-PE-induced cytotoxicity is reduced by TNF-alpha neutralizing antibodies, indicating the involvement of TNF-alpha. Thus our results suggest that the different potencies of LPS and MTP-PE as immunomodulators probably result from different actions on Kupffer cells, resulting in differences in the amounts and kinetics of released TNF-alpha and PGE2, and that PGE2 plays an important regulatory role in the action of LPS, but not in the actions of MTP-PE.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10815618      PMCID: PMC1781814          DOI: 10.1080/09629359990306

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  34 in total

1.  Prostaglandin release but not superoxide production by rat Kupffer cells stimulated in vitro depends on Na+/H+ exchange.

Authors:  P Dieter; A Schulze-Specking; U Karck; K Decker
Journal:  Eur J Biochem       Date:  1987-12-30

2.  The lipophilic muramyl peptide MTP-PE is a potent inhibitor of HIV replication in macrophages.

Authors:  J K Lazdins; K Woods-Cook; M Walker; E Alteri
Journal:  AIDS Res Hum Retroviruses       Date:  1990-10       Impact factor: 2.205

Review 3.  Biologically active products of stimulated liver macrophages (Kupffer cells).

Authors:  K Decker
Journal:  Eur J Biochem       Date:  1990-09-11

4.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

5.  Interdependence of tumor necrosis factor, prostaglandin E2, and protein synthesis in lipopolysaccharide-exposed rat Kupffer cells.

Authors:  T Peters; U Karck; K Decker
Journal:  Eur J Biochem       Date:  1990-08-17

6.  Comparison of in vitro cell cytotoxic assays for tumor necrosis factor.

Authors:  D A Flick; G E Gifford
Journal:  J Immunol Methods       Date:  1984-03-30       Impact factor: 2.303

7.  Time course of cellular distribution of endotoxin in liver, lungs and kidneys of rats.

Authors:  M A Freudenberg; N Freudenberg; C Galanos
Journal:  Br J Exp Pathol       Date:  1982-02

8.  Virus-vs endotoxin-induced activation of liver macrophages.

Authors:  K J Busam; A Homfeld; R Zawatzky; S Kästner; J Bauer; W Gerok; K Decker
Journal:  Eur J Biochem       Date:  1990-08-17

9.  Rat hepatic sinusoidal endothelial cells in monolayer culture. Biochemical and ultrastructural characteristics.

Authors:  S Eyhorn; H J Schlayer; H P Henninger; P Dieter; R Hermann; M Woort-Menker; H Becker; H E Schaefer; K Decker
Journal:  J Hepatol       Date:  1988-02       Impact factor: 25.083

10.  Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice.

Authors:  W E Fogler; R Wade; D E Brundish; I J Fidler
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

View more
  5 in total

Review 1.  Mifamurtide: a review of its use in the treatment of osteosarcoma.

Authors:  James E Frampton
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

Review 2.  Mifamurtide for the treatment of nonmetastatic osteosarcoma.

Authors:  Kosei Ando; Kanji Mori; Nedège Corradini; Françoise Redini; Dominique Heymann
Journal:  Expert Opin Pharmacother       Date:  2011-02       Impact factor: 3.889

3.  Inhibition of lipopolysaccharide-inducible nitric oxide synthase, TNF-alpha and COX-2 expression by sauchinone effects on I-kappaBalpha phosphorylation, C/EBP and AP-1 activation.

Authors:  Ae Kyung Lee; Sang Hyun Sung; Young Choong Kim; Sang Geon Kim
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

4.  Post-hepatectomy liver regeneration in the context of bile acid homeostasis and the gut-liver signaling axis.

Authors:  Lianne de Haan; Sarah J van der Lely; Anne-Loes K Warps; Quincy Hofsink; Pim B Olthof; Mark J de Keijzer; Daniël A Lionarons; Lionel Mendes-Dias; Bote G Bruinsma; Korkut Uygun; Hartmut Jaeschke; Geoffrey C Farrell; Narci Teoh; Rowan F van Golen; Tiangang Li; Michal Heger
Journal:  J Clin Transl Res       Date:  2018-02-16

5.  A multiple drug loaded, functionalized pH-sensitive nanocarrier as therapeutic and epigenetic modulator for osteosarcoma.

Authors:  Ye Yuan; Jia-Xing Song; Mei-Na Zhang; Bao-Shan Yuan
Journal:  Sci Rep       Date:  2020-09-23       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.